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Abstract
Previous studies on commensal Escherichia coli from healthy children in the Bolivian Chaco have shown remarkable resistance rates to the
old antibiotics since the early 1990s, and the emergence of resistance to newer drugs (ﬂuoroquinolones and expanded-spectrum cephalo-
sporins) in the 2000s. Here we report the results of a new survey conducted in 2011 in the same setting. Rectal swabs were obtained from
482 healthy children (aged 6–72 months) from three urban areas of the Bolivian Chaco. Screening for antibiotic-resistant E. coli was per-
formed by a direct plating method, as in the previous studies. The blaCTX-M genes were investigated by PCR/sequencing, and CTX-M-
producing isolates were subjected to genotyping and detection of several plasmid-mediated quinolone resistance mechanisms. Results
showed high rates of resistance to nalidixic acid (76%), ciproﬂoxacin (44%) and expanded-spectrum cephalosporins (12.4%), demonstrating
a relentless increase of resistance to those drugs over the past two decades. CTX-M-type extended-spectrum beta-lactamases were found
to be widespread (12%, 97% of extended-spectrum beta-lactamase producers). Compared with the previous studies, CTX-M-producing
E. coli underwent a dramatic dissemination (120-fold increase since early 2000s) and a radical change of dominant CTX-M groups (CTX-M-
1 and CTX-M-9 groups versus CTX-M-2 group). Most CTX-M producers were not susceptible to quinolones (91%), and 55% carried plas-
mid-mediated quinolone resistance genes (different combinations of aac(6¢)-Ib-cr, qnrB and qepA). This study shows the rapid and remarkable
increasing trend for resistance to ﬂuoroquinolones and expanded-spectrum cephalosporins in one of the poorest regions of Latin America,
and underscores the need for urgent control strategies aimed at preserving the efﬁcacy of those drugs in similar settings.
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Introduction
Increasing antibiotic resistance is a global public health con-
cern, with particularly serious consequences in countries of
limited resources, where resistance has dramatic effects on
morbidity and mortality rates and threatens the viability of
local healthcare systems [1,2].
Surveillance of antibiotic resistance is a crucial element for
the implementation of intervention strategies aimed at preserv-
ing the efﬁcacy of antibiotics [1]. Beside clinical isolates, there is
increasing agreement about the importance of monitoring com-
mensal bacteria, which constitute a reservoir not only of resis-
tant strains that can cause infections but also of resistance
genes that are potentially transferable to pathogens [1,3].
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From this perspective, several studies have monitored
resistance in commensal Escherichia coli, which is the pre-
dominant aerobic species of the gut, in addition to being one
of the most common pathogens both in hospital and in com-
munity settings [3]. Reliable, simple and low-cost methods
for investigating resistance in commensal E. coli have been
implemented and were shown to represent a valid tool for
performing large-scale surveillance studies in resource-limited
settings (where microbiological diagnosis is usually not per-
formed, and data on antibiotic resistance are scarce or
totally absent) [4–6].
In previous studies aimed at monitoring antibiotic resis-
tance in commensal E. coli from healthy children in the Boliv-
ian Chaco, we observed very high rates of resistance to the
old antibiotics (i.e. ampicillin, tetracycline, trimethoprim-sul-
phamethoxazole, chloramphenicol) since the early 1990s, and
the emergence of resistance to newer drugs (namely ﬂuor-
oquinolones and expanded-spectrum cephalosporins) in the
2000s [5–7]. Further studies demonstrated that resistance to
expanded-spectrum cephalosporins in commensal E. coli from
that setting was mainly related to the emergence of CTX-M-
type extended-spectrum beta-lactamase (ESBL) determinants
[8,9].
Here we report on the dramatic increase of resistance to
ﬂuoroquinolones and expanded-spectrum cephalosporins
shown by a new survey conducted in 2011 in the same area,
and describe the molecular epidemiology of the widespread
dissemination of CTX-M-type ESBLs that occurred in that
setting.
Materials and Methods
Study design and population
The study was conducted in March 2011 in three urban
areas of the Bolivian Chaco: Camiri (Santa Cruz Department,
c. 34 000 inhabitants), Villa Montes (Tarija Department,
c. 25 000 inhabitants) and Monteagudo (Chuquisaca Depart-
ment, c. 11 500 inhabitants). Although located in different
Departments, the three urban areas are connected by roads
(distances of about 100 km from Camiri to Monteagudo, and
about 160 km from Camiri to Villa Montes) which favour
exchanges of goods and people. As in previous surveys [5–
7], the study population was represented by children (160,
156 and 166 from Camiri, Villa Montes and Monteagudo,
respectively), aged 6–72 months, who have not had diar-
rhoea in the previous 24 h. Only one child in the target age
cohort per household was included. The studied households
were selected by a modiﬁed cluster sampling, as described
previously [5]. A rectal swab was obtained from each
enrolled child, after informed consent was obtained from
parents or legal guardians, who were also interviewed about
antibiotics possibly administered to the child during the pre-
vious 2 weeks. In case of antibiotics consumption, parents/
legal guardians were also interviewed about antibiotic pre-
scription. Full ethical clearance was obtained from the quali-
ﬁed local authorities (Convenio de Salud, Ministerio de
Salud—Vicariato de Camiri) who revised and approved the
study design.
Screening for faecal carriage of antibiotic-resistant E. coli
Screening for the presence of antibiotic-resistant E. coli in
the faecal samples was performed by a direct plating method
(essentially based on direct application of antibiotic disks
onto a MacConkey No. 3 agar plate inoculated with the fae-
cal swab), as described previously [4,5]. Antibiotics tested
are listed in Table 1.
Characterization of ESBL-producing E. coli
All samples showing the presence of isolates with reduced
susceptibility to expanded-spectrum cephalosporins (n = 60)
were further plated onto MacConkey no. 3 agar plates con-
taining ceftriaxone 2 lg/mL, and one isolated coliform colony
per sample was collected. Identiﬁcation was conﬁrmed by
TABLE 1. Antibiotic resistance rates in commensal Escherichia coli from healthy children in the Bolivian Chaco over the past
two decades
Year
No. of studied
children
Urban areas
(no. of children)a
Antibiotic resistance rates (%)b
ReferenceAMP TET SXT CHL NAL CIP ESC
1992 296 C (296) 97 92 94 69 4 0 0 [7]
2002 1594 C (794), VM (790) 97 94 96 70 36 16 0.1 [5]
2005 1600 C (800), VM (800) 97 92 94 67 51 26 1.9 [6]
2011 482 C (160), VM (156), M (166) 98 95 94 78 76 44c 12d This study
aC, Camiri; VM, Villa Montes; M, Monteagudo.
bAMP, ampicillin; TET, tetracycline; SXT, trimethoprim-sulphamethoxazole; CHL, chloramphenicol; NAL, nalidixic acid; CIP, ciproﬂoxacin; ESC, expanded-spectrum cephalo-
sporins (ceftriaxone and/or ceftazidime).
cCamiri 39%, Villa Montes 40%, Monteagudo 51%.
dCamiri 9%, Villa Montes 17%, Monteagudo 11%.
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the API20E identiﬁcation system (bioMe´rieux, Marcy l’E´toile,
France). ESBL conﬁrmatory tests were performed according
to CLSI [10]. Identiﬁcation of CTX-M-type determinants and
characterization of CTX-M groups was carried out by PCR
[9,11], followed by complete sequencing of blaCTX-M genes.
Primers designed in this study were used for ampliﬁcation
and sequencing of variants belonging to the CTX-M-9 group
(5¢-GATGTAACACGGATTGACC and 5¢- GAACTTTTG
CTGAGTTGAAGG) and CTX-M-8 group (5¢-CACGG
ATTCAATTTTCAGGAG and 5¢-GAGCGCTCCACATT
TTTTAG), whereas other groups were sequenced as
described previously [9]. Genotyping of CTX-M producers
was performed by determination of the main E. coli
phylogenetic groups (A, B1, B2, D) according to the Clermont
method [9], random ampliﬁcation of polymorphic DNA
(RAPD) with the 1290 and 1254 decamers [9], and multilocus
sequence typing using protocols and conditions described on
the E. coli multilocus sequence typing website [http://mlst.ucc.
ie/mlst/dbs/Ecoli/documents/primersColi_html].
All CTX-M producers were also investigated for quino-
lone susceptibility by the disk diffusion method [10,12], and
for the presence of plasmid-mediated quinolone resistance
genes by PCR, as described previously (qnrA, qnrB, qnrS,
aac(6¢)-Ib-cr, qepA [13]; qnrC [14]; qnrD [15]).
Statistical analysis
Data entry and analysis were performed with the EPI INFO
software package version 2008 (Centers for Disease Control
and Prevention, Atlanta, GA, USA). Statistical differences
were determined by the chi-squared test.
Results and Discussion
Evolution of antibiotic resistance rates in commensal E. coli
from healthy children in the Bolivian Chaco over the past
two decades
The 2011 survey conﬁrmed the very high resistance rates to
the old antibiotics (i.e. ampicillin, tetracycline, trimethoprim-
sulphamethoxazole, chloramphenicol) recorded in the previ-
ous studies [5–7], and showed an alarmingly relentless
increase of resistance to quinolones (including ﬂuoroquinol-
ones) and expanded-spectrum cephalosporins (Table 1). In
particular, E. coli isolates with acquired resistance to nalidixic
acid, ciproﬂoxacin and expanded-spectrum cephalosporins
were found in 76%, 44% and 12.4% of enrolled children,
respectively (p <0.0001 compared with the 2005 survey).
Resistance rates were overall similar in the three urban areas
studied, with the exception of higher resistance rates
observed for ciproﬂoxacin in Monteagudo (statistically signiﬁ-
cant, p <0.05) and for expanded-spectrum cephalosporins in
Villa Montes (statistically signiﬁcant compared with Camiri,
p 0.03) (Table 1).
Data from interviews showed that 33% of children had
been administered antibiotics during the 2 weeks preceding
the study: 17% had received beta-lactams (14% ampicillin, 3%
penicillin, 1% expanded-spectrum cephalosporins), 11% tri-
methoprim-sulphamethoxazole, 2% erythromycin, 2% tetra-
cyclines and 2% other antibiotics (including nalidixic acid,
chloramphenicol, metronidazole and aminoglycosides). Data
on antibiotic prescription were available for 89% of children
who received antibiotics, and showed that they were mostly
prescribed by doctors (83%), although in some cases they
were recommended by other healthcare providers (nurse
3%, ‘promotor de salud’ 5%), pharmacy staff (2%), or were
taken without prescription (7%).
Household antibiotic use in the three urban areas was
overall comparable, except for a signiﬁcantly higher use of
ampicillin in Villa Montes (p 0.005 and p 0.002 compared
with Camiri and Monteagudo, respectively), which could pos-
sibly have contributed to the higher level of resistance to
expanded-spectrum cephalosporins observed in this urban
area. However, no signiﬁcant difference in carriage of isolates
resistant to expanded-spectrum cephalosporins was
observed between children who had been administered
ampicillin in the 2 weeks preceding the survey and those
who had not (p 0.21), excluding a direct role of ampicillin in
promoting colonization by CTX-M producers. The reasons
for the higher resistance rates to ﬂuoroquinolones observed
in Monteagudo remain unclear and will be the subject of fur-
ther studies.
Increasing resistance to ﬂuoroquinolones and expanded-
spectrum cephalosporins in clinical isolates of Enterobacteria-
ceae is an emerging worldwide phenomenon affecting the
management of both hospital-acquired and community-
acquired infections, and intestinal colonization has been
found to represent a risk factor for subsequent infections
caused by those resistant microorganisms [3]. The results
from this study underscore the magnitude of such a relevant
phenomenon in one of the poorest regions of Latin America,
calling for urgent control strategies aimed at preserving the
efﬁcacy of ﬂuoroquinolones and expanded-spectrum cephalo-
sporins in similar settings, where alternative therapeutic
options are often unavailable or too expensive.
Dramatic increase and changed epidemiology of CTX-M-
type ESBLs
Of the 60 children carrying isolates with reduced suscep-
tibility to expanded-spectrum cephalosporins, 58 (97%)
were found to be colonized by CTX-M-producing E. coli.
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The remaining two children carried E. coli isolates pro-
ducing other types of ESBLs, which were not further
investigated.
Characterization of blaCTX-M genes identiﬁed variants
belonging to CTX-M-1 (n = 25, 43%), CTX-M-9 (n = 25,
43%), CTX-M-8 (n = 7, 12%) and CTX-M-2 (n = 2, 3%)
groups, with one isolate carrying blaCTX-M genes of different
groups (CTX-M-1 and CTX-M-9 groups) (Tables 2 and 3).
No signiﬁcant difference in the distribution of CTX-M groups
among the three study areas was observed, although CTX-
M-2 and CTX-M-8 groups were not detected in Monteagudo
and Camiri, respectively.
TABLE 2. Dissemination and changed epidemiology of CTX-M-type extended spectrum beta-lactamases in commensal Escheri-
chia coli from healthy children in the Bolivian Chaco
Year
No. of
studied
children
% of carriers
of ESC-resistant
E. coli (n)a
% of carriers of
CTX-M-producing
E. coli (n)
Distribution of different CTX-M-groups (%)b
ReferenceCTX-M-1 CTX-M-2 CTX-M-8 CTX-M-9
1992 296 0 0 0 0 0 0 [7]
2002 1594 0.1 (2) 0.1 (2) 0 100 0 0 [8]
2005 1600 1.9 (30) 1.6 (26) 38 62 0 0 [9]
2011 482 12.4 (60) 12.0 (58) 43 3 12 43 This study
aESC, expanded-spectrum cephalosporins (ceftriaxone and/or ceftazidime).
bPrevalence of each CTX-M group over the total number of children carrying CTX-M-producing E. coli. In the 2011 study, one E. coli isolate harboured blaCTX-M genes of dif-
ferent groups (CTX-M-1 and CTX-M-9 groups).
TABLE 3. Features of CTX-M-producing Escherichia coli from the 2011 survey
Group CTX-M type
RAPD type
(no. of isolates)
Phylogenetic
group
Origin
(no. of isolates)a
Resistance to
quinolonesb PMQR genesc
CTX-M-1 CTX-M-15 1 (6) A C (3), VM (1), M (2) NAL/CIP aac(6¢)-Ib-cr
2 (2) A VM (2) NAL/CIP aac(6¢)-Ib-cr
3 (1) A VM (1) NAL/CIP aac(6¢)-Ib-cr
4 (2) A VM (1), M (1) NAL/CIP aac(6¢)-Ib-cr
5 (3) A VM (1), M (2) NAL/CIP aac(6¢)-Ib-cr
6 (1) A C (1) NAL/CIP aac(6¢)-Ib-cr
7 (1) A VM (1) NAL/CIP aac(6¢)-Ib-cr
8 (1) A VM (1) NAL/CIP aac(6¢)-Ib-cr
9 (1) A M (1) NAL/CIP qnrB, aac(6¢)-Ib-cr
10 (2) A M (2) NAL/CIP qepA
11 (1) A C (1) NAL/CIP aac(6¢)-Ib-cr
12 (1) B1 M (1) nal qnrB, aac(6¢)-Ib-cr
13 (1) D VM (1) NAL/CIP qepA
CTX-M-3 14 (1) A M (1) – –
CTX-M-9 CTX-M-65 15 (1) A C (1) NAL/CIP qnrB
16 (1) A C (1) nal qnrB
17 (1) A VM (1) – –
18 (1) A VM (1) NAL/CIP –
19 (1) A VM (1) NAL/cip qnrB
20 (1) A M (1) NAL/CIP –
21 (1) A M (1) - –
22 (4) B1 VM (3), M (1) NAL/CIP –
23 (2) B1 C (1), M (1) NAL –
24 (2) B1 C (2) NAL/CIP –
25 (1) B1 VM (1) NAL/CIP –
26 (1) B1 M (1) NAL/CIP –
27 (2) D C (2) NAL/CIP –
28 (1) D C (1) NAL/CIP –
CTX-M-14 29 (1) A VM (1) NAL/CIP –
30 (1) B1 VM (1) NAL/CIP –
31 (1) B1 VM (1) NAL –
32 (1) D M (1) NAL/CIP qepA
CTX-M-8 CTX-M-8 33 (1) A VM (1) NAL/CIP qnrB
34 (1) A VM (1) NAL/cip qnrB
35 (1) A VM (1) NAL/CIP qnrB
36 (1) A M (1) – –
37 (1) B1 VM (1) NAL/CIP –
38 (1) D VM (1) NAL/CIP –
39 (1) D M (1) – –
CTX-M-2 CTX-M-2 40 (1) D C (1) nal/cip qnrB
41 (1) D VM (1) NAL/CIP -
CTX-M-1+CTX-M-9 CTX-M-15+CTX-M-14 42 (1) D VM (1) NAL/CIP qepA, aac(6¢)-Ib-cr
aC, Camiri; VM, Villa Montes; M, Monteagudo.
bNAL, nalidixic acid; CIP, ciproﬂoxacin. Resistant and intermediate phenotypes are indicated in upper-case and lower-case letters, respectively.
cPMQR, plasmid-mediated quinolone resistance.
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Sequence analysis of blaCTX-M genes identiﬁed blaCTX-M-15
(n = 24), blaCTX-M-65 (n = 20), blaCTX-M-8 (n = 7), blaCTX-M-14
(n = 5), blaCTX-M-2 (n = 2) and blaCTX-M-3 (n = 1) (Table 3).
Phylogenetic grouping and RAPD typing revealed an overall
genetic heterogeneity among CTX-M producers, although
some events of clonal expansion were observed (mainly
among CTX-M-15 producers) (Table 3). Multilocus
sequence typing analysis of two CTX-M-15-producing iso-
lates of phylogenetic group A (the most prevalent phyloge-
netic group among CTX-M-15 producers) identiﬁed ST10
(RAPD type 1) and ST617 (RAPD type 6). ST617 was also
assigned to a CTX-M-15-producing isolate of phylogenetic
group A from the 2005 survey (representative of an RAPD
type circulating both in Camiri and Villa Montes [9]),
although the RAPD pattern apparently differed from that of
the ST617 isolate collected in 2011 (data not shown). ST10
and ST617 belong to the ST10 complex, which has recently
been found to represent the predominant sequence type
among E. coli isolates assigned to phylogenetic group A
[16]. Two CTX-M-65-producing isolates of phylogenetic
group B1 (the most prevalent phylogenetic group among
CTX-M-65 producers) were assigned to ST602 (RAPD type
22) and ST58 (RAPD type 23).
Most CTX-M producers were non-susceptible to quinol-
ones (91%), and more than half (55%) were shown to carry
one of the plasmid-mediated quinolone resistance genes
investigated: aac(6¢)-Ib-cr (n = 21), qnrB (n = 9) and qepA
(n = 5) (Table 3). In particular, aac(6¢)-Ib-cr was identiﬁed in
21 of the 24 CTX-M-15-producing isolates (suggesting a pos-
sible genetic linkage between the two resistance determi-
nants), whereas qnrB and qepA were found in isolates
producing different CTX-M variants.
Results from this study demonstrate that, after their ﬁrst
appearance in 2002 [8], CTX-M-type ESBLs underwent a
dramatic dissemination in the Bolivian Chaco during the last
decade (from 0.1 to 12%, 120-fold, p <0.0001). Further-
more, the present ﬁndings underscore the complex dynam-
ics of CTX-M-type ESBL dissemination in the study setting,
with the remarkably increased prevalence being associated
with a radical change of circulating CTX-M groups. CTX-M-
1 and CTX-M-9 groups are emerging worldwide as the
dominant CTX-M variants [17]. Here, we demonstrated
that those CTX-M groups have successfully spread also in
Bolivia, where they have almost completely replaced the
CTX-M-2 group, which has been endemic and historically
dominant in clinical isolates of Enterobacteriaceae in Latin
America since the ﬁrst identiﬁcation of the CTX-M-2 vari-
ant in Argentina in the late 1980s [18]. The reasons
accounting for the remarkable dissemination of CTX-M-type
ESBLs in the study area are not easy to investigate because
of the difﬁculties in collecting reliable data on drug con-
sumption. Further studies on the genetic supports of
blaCTX-M genes will be performed to investigate the possible
causes for the changed molecular epidemiology of CTX-M
enzymes in that setting. To the best of our knowledge, this
is also the ﬁrst report of blaCTX-M-65 and qepA genes in
South America.
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